Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
On August 3, 2021, Cue Biopharma (Nasdaq: CUE) announced participation in the BTIG Virtual Biotechnology Conference scheduled for August 9-10, 2021. During the fireside chat on August 10, at 3:00 p.m. EDT, the company will share updates on its clinical programs, particularly the CUE-101 therapeutic for HPV+ recurrent head and neck cancer. The discussion will also cover advancements in their pipeline, including the upcoming Phase 1 trial for CUE-102 targeting the Wilms' tumor 1 (WT1) antigen expected to start in early 2022.
- None.
- None.
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.
During the fireside chat, Cue Biopharma will provide a corporate update highlighting clinical progress on CUE-101, the lead Immuno-STAT™ (Selective Targeting and Alteration of T cells) IL-2 based therapeutic, in clinical trials for the treatment of second line and beyond patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on the Company’s platform developments and pipeline progress including its next clinical candidate CUE-102, targeting the Wilms’ tumor 1 (WT1) antigen, which will be evaluated in a Phase 1 clinical trial expected to commence in 1H22.
Presentation Details
BTIG Virtual Biotechnology Conference
Date and Time: Tuesday, August 10, 2021 at 3:00 p.m. EDT
The webcasted fireside chat will be hosted on the conference website and available only to conference participants. Please visit www.BTIG.com for more information.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.
Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com
Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com
FAQ
When is Cue Biopharma's fireside chat at the BTIG Virtual Biotechnology Conference?
What will Cue Biopharma discuss during the BTIG Conference?
What is CUE-101 being developed for?
What is the focus of Cue Biopharma's pipeline development?
When is the Phase 1 clinical trial for CUE-102 expected to start?
